{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:08:39Z","timestamp":1777036119777,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy with a bimodal distribution of incidence in both pediatric\/young adult and elderly patient populations. Despite the high complete remission rate, there is a high rate of relapse necessitating a need for therapy options in the relapsed\/refractory setting. Given this, treatment paradigms for ALL have shifted towards targeted therapies and away from high-intensity chemotherapy. The efficacy of inotuzumab ozogamicin (InO) in the relapsed\/refractory setting for pediatric and adult populations has led to incorporation of this targeted therapy into frontline regimens. In this review, the role of InO in the frontline, measurable residual disease (MRD) positive and relapsed\/refractory settings is highlighted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>InO is a directed antibody-drug conjugate that binds to CD22 on the surface of leukemic blasts. The cell internalizes InO, prompting enzymatic cleavage in the lysosome that releases calicheamicin, inducing double-strand DNA breaks and causing apoptosis. However, off-target effects can lead to severe adverse events such as hepatotoxicity, including veno-occlusive disease, and myelosuppression. Prior studies have supported its use in the relapsed or refractory treatment setting; however, newer studies incorporating InO in the frontline have shown promising results. Newer studies have also shown evidence of utilization of InO in specific sub-populations of B-cell ALL, including those with MRD-positive disease and Philadelphia-positive (Ph +) disease, and as bridging therapy with CAR T-cell therapy, and in the post-transplant maintenance setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review evaluated the effectiveness of InO in clinical practice, associated adverse events, future directions in specific patient populations. Despite recent advancements, patients with B-cell ALL tend to have poorer outcomes, especially in the adult population. Future research and larger scale prospective studies are indicated to evaluate the efficacy of InO in different lines of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-026-00772-7","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:03:08Z","timestamp":1771902188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inotuzumab Ozogamicin in Clinical Practice: an Overview of Efficacy, Safety, and Real-World Applications"],"prefix":"10.1007","volume":"21","author":[{"given":"Valerie","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandan","family":"Srinivasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"772_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013. https:\/\/doi.org\/10.1016\/S0140-6736(12)62187-4.","journal-title":"Lancet"},{"issue":"3","key":"772_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","volume":"12","author":"LM Man","year":"2017","unstructured":"Man LM, Morris AL, Keng M. New therapeutic strategies in acute lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(3):197\u2013206. https:\/\/doi.org\/10.1007\/s11899-017-0380-3.","journal-title":"Curr Hematol Malig Rep"},{"key":"772_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01552-7","volume":"17","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol. 2024;17:32. https:\/\/doi.org\/10.1186\/s13045-024-01552-7.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"772_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111(4):1827\u201333. https:\/\/doi.org\/10.1182\/blood-2007-10-116582.","journal-title":"Blood"},{"issue":"20","key":"772_CR5","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075\u201386. https:\/\/doi.org\/10.1200\/JCO.2004.10.050.","journal-title":"J Clin Oncol"},{"issue":"15","key":"772_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"JM Ribera","year":"2014","unstructured":"Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595\u2013604. https:\/\/doi.org\/10.1200\/JCO.2013.52.2425.","journal-title":"J Clin Oncol"},{"issue":"14","key":"772_CR7","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/cncr.30031","volume":"122","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with Relapsed\/Refractory B-precursor acute lymphoblastic leukemia: results from two phase 2 studies. Cancer. 2016;122(14):2178\u201385. https:\/\/doi.org\/10.1002\/cncr.30031.","journal-title":"Cancer"},{"issue":"2","key":"772_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","volume":"19","author":"H Kantarjian","year":"2018","unstructured":"Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab Ozogamicin in combination with Low-Intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with Philadelphia Chromosome-Negative acute lymphoblastic leukemia: A Single-Arm, phase II study. Lancet Oncol. 2018;19(2):240\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(18)30011-1.","journal-title":"Lancet Oncol"},{"issue":"14","key":"772_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603\u201310. https:\/\/doi.org\/10.1007\/s40265-017-0802-5.","journal-title":"Drugs"},{"issue":"14","key":"772_CR10","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow\u2010up from the randomized, phase 3 INO\u2010VATE study. Cancer. 2019;125(14):2474\u201387. https:\/\/doi.org\/10.1002\/cncr.32116.","journal-title":"Cancer"},{"key":"772_CR11","unstructured":"labeling.pfizer.com\/ShowLabeling.aspx?id\u2009=\u20099503. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=9503. Accessed 26 May 2025."},{"issue":"8","key":"772_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"issue":"2","key":"772_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/hep.30222","volume":"69","author":"GB McDonald","year":"2019","unstructured":"McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with ANTI-CD22-calicheamicin (inotuzumab ozogamicin). Hepatol Baltim Md. 2019;69(2):831\u201344. https:\/\/doi.org\/10.1002\/hep.30222.","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"772_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bjh.16557","volume":"190","author":"MS Cairo","year":"2020","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic sos\/vod after haematopoietic cell transplantation. Br J Haematol. 2020;190(6):822\u201336. https:\/\/doi.org\/10.1111\/bjh.16557.","journal-title":"Br J Haematol"},{"issue":"9","key":"772_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020.","volume":"25","author":"DI Marks","year":"2019","unstructured":"Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2019.04.020.","journal-title":"Biol Blood Marrow Transplant"},{"key":"772_CR16","unstructured":"Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT). - ASCO. https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT341381.\u00a0Accessed 26 May 2025."},{"key":"772_CR17","unstructured":"Use of Ursodiol for SOS\/VOD Prophylaxis in Patients with Acute Leukemia Receiving Gemtuzumab-Ozogamicin or Inotuzumab-Ozogamicin. Published online March 23. 2023. https:\/\/jhoponline.com\/issue-archive\/2023-issues\/march-2023-vol-13-special-feature\/use-of-ursodiol-for-sos-vod-prophylaxis-in-patients-with-acute-leukemia-receiving-gemtuzumab-ozogamicin-or-inotuzumab-ozogamicin. Accessed 26 May 2025."},{"key":"772_CR18","unstructured":"defitelio.en.USPI.pdf. https:\/\/pp.jazzpharma.com\/pi\/defitelio.en.USPI.pdf. Accessed 26 May 2025."},{"issue":"20","key":"772_CR19","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0486.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"772_CR20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-16-0939","volume":"23","author":"M Guffroy","year":"2017","unstructured":"Guffroy M, Falahatpisheh H, Biddle K, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0939.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"772_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905\u201313. https:\/\/doi.org\/10.1002\/cncr.33321.","journal-title":"Cancer"},{"issue":"15","key":"772_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017;1(15):1167\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2016001925.","journal-title":"Blood Adv"},{"issue":"8","key":"772_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajh.26238","volume":"96","author":"N Jain","year":"2021","unstructured":"Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96(8):1000\u20137. https:\/\/doi.org\/10.1002\/ajh.26238.","journal-title":"Am J Hematol"},{"issue":"3","key":"772_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547\u2013547. https:\/\/doi.org\/10.1200\/JCO.2000.18.3.547.","journal-title":"J Clin Oncol"},{"issue":"8","key":"772_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/cncr.23819","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097\u2013101. https:\/\/doi.org\/10.1002\/cncr.23819.","journal-title":"Cancer"},{"issue":"5","key":"772_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","volume":"4","author":"SE Siegel","year":"2018","unstructured":"Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia. JAMA Oncol. 2018;4(5):725\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5305.","journal-title":"JAMA Oncol"},{"issue":"14","key":"772_CR27","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548\u201359. https:\/\/doi.org\/10.1182\/blood-2018-10-881961.","journal-title":"Blood"},{"issue":"Supplement 1","key":"772_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209438","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS, et al. Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial. Blood. 2024;144(Supplement 1):308. https:\/\/doi.org\/10.1182\/blood-2024-209438.","journal-title":"Blood"},{"issue":"Supplement 1","key":"772_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2024-208742","volume":"144","author":"J Senapati","year":"2024","unstructured":"Senapati J, Jabbour E, Short NJ, et al. Chemotherapy free regimen of inotuzumab Ozogamicin and blinatumomab in frontline therapy of older patients with Philadelphia negative B-Cell acute lymphoblastic leukemia. Blood. 2024;144(Supplement 1):1442. https:\/\/doi.org\/10.1182\/blood-2024-208742.","journal-title":"Blood"},{"issue":"16suppl","key":"772_CR30","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","volume":"41","author":"MJ Wieduwilt","year":"2023","unstructured":"Wieduwilt MJ, Yin J, Kour O, et al. Chemotherapy-free treatment with inotuzumab Ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703. J Clin Oncol. 2023;41(16suppl):7006\u20137006. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7006.","journal-title":"J Clin Oncol"},{"issue":"3","key":"772_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013negative B-precursor ALL. J Clin Oncol. 2024;42(3):273\u201382. https:\/\/doi.org\/10.1200\/JCO.23.00546.","journal-title":"J Clin Oncol"},{"issue":"1","key":"772_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2022-158934","volume":"140","author":"N Goekbuget","year":"2022","unstructured":"Goekbuget N, Viardot A, Steffen B, et al. <article-title update=\"added\">Outcome of 841 older patients (>55 yrs) with newly diagnosed Ph\/BCR-ABL negative ALL prospectively treated according to pediatric-based, age-adapted GMALL protocols. Blood. 2022;140(1):121\u20133. https:\/\/doi.org\/10.1182\/blood-2022-158934.","journal-title":"Blood"},{"issue":"2","key":"772_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","volume":"142","author":"J Holowiecki","year":"2008","unstructured":"Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study. Br J Haematol. 2008;142(2):227\u201337. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07185.x.","journal-title":"Br J Haematol"},{"issue":"7","key":"772_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia. JAMA Oncol. 2017;3(7):e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580.","journal-title":"JAMA Oncol"},{"issue":"5","key":"772_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143(5):417\u201321. https:\/\/doi.org\/10.1182\/blood.2023022330.","journal-title":"Blood"},{"issue":"1","key":"772_CR36","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1182\/blood-2022-157937","volume":"140","author":"G Marconi","year":"2022","unstructured":"Marconi G, Piciocchi A, Chiaretti S, et al. Gimema ALL2418: interim analysis of a phase Iia study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation. Blood. 2022;140(1):6119\u201321. https:\/\/doi.org\/10.1182\/blood-2022-157937.","journal-title":"Blood"},{"issue":"10299","key":"772_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"issue":"23","key":"772_CR38","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","volume":"8","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Roloff GW, Faramand R, et al. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024;8(23):6139\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2024013747.","journal-title":"Blood Adv"},{"issue":"23","key":"772_CR39","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1182\/bloodadvances.2024014237","volume":"8","author":"DI Marks","year":"2024","unstructured":"Marks DI, Castleton AZ. Impact of prior treatment on CAR T-cell outcome in adult ALL. Blood Adv. 2024;8(23):6137\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2024014237.","journal-title":"Blood Adv"},{"issue":"1","key":"772_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01038-2","volume":"14","author":"M Oporto Espuelas","year":"2024","unstructured":"Oporto Espuelas M, Burridge S, Kirkwood AA, et al. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme. Blood Cancer J. 2024;14(1):66. https:\/\/doi.org\/10.1038\/s41408-024-01038-2.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"772_CR41","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2024-201514","volume":"144","author":"JH Park","year":"2024","unstructured":"Park JH, Jabbour E, Shaughnessy P, et al. Obecabtagene autoleucel (obe-cel) for adult relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) in the open-label, multi-center, global, single-arm, phase Ib\/II FELIX study: the impact of bridging therapies on CAR T-cell expansion and persistence. Blood. 2024;144(Supplement 1):3458. https:\/\/doi.org\/10.1182\/blood-2024-201514.","journal-title":"Blood"},{"issue":"1","key":"772_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","volume":"6","author":"MJ Wieduwilt","year":"2022","unstructured":"Wieduwilt MJ, Metheny L, Zhang MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6(1):339\u201357. https:\/\/doi.org\/10.1182\/bloodadvances.2021004916.","journal-title":"Blood Adv"},{"issue":"5","key":"772_CR43","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bmt.2012.195","volume":"48","author":"L Poon","year":"2013","unstructured":"Poon L, Bassett R, Rondon G, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). Bone Marrow Transpl. 2013;48(5):666\u201370. https:\/\/doi.org\/10.1038\/bmt.2012.195.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"772_CR44","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","volume":"8","author":"LL Metheny","year":"2024","unstructured":"Metheny LL, Sobecks R, Cho C, et al. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8(6):1384\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2023011514.","journal-title":"Blood Adv"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00772-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00772-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00772-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:03:39Z","timestamp":1771945419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00772-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00772-7","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Caroline Tatum, PharmD: The Association of Cancer Care Centers (consultant), The National Community Oncology Dispensing Association (consultant).\u00a0Nandan Srinivasa, MD: Rivanna Medical LLC (Expert Consultant).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}